Manhattan —
The Trans-Pacific Partnership deal recently struck by President Obama has spurred contention on multiple fronts – including within the prescription drug market.
The treaty would extend patent protections on certain prescription medications – spurring fears that prices will rise, making them less affordable, especially for the poor.
Doctors, medical students and activists convened outside pharmaceutical giant Pfizer’s Manhattan headquarters to voice opposition to the dozen-nation trade pact, which is subject to the approval of Congress.
